Figure S3 from Epigenetic Silencing of <i>THY1</i> Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44<sup>+</sup>/CD24<sup>low</sup>/CD90<sup>+</sup> Myoepithelial Cells
Micaela Montanari(University of Naples Federico II), Bianca Maria Veneziani(Federico II University Hospital), Roberto Bianco(Federico II University Hospital), Meghana V. Trivedi(University of Houston), Vittoria Carbone(University of Naples Federico II), Luigi Coppola(Synlab Czech (Czechia)), Agostina Nardone(AstraZeneca (Spain)), Grazia Arpino(University of Naples Federico II), Corrado Garbi, Sabino De Placido, Rossella Lauria, Enrico V. Avvedimento(University of Naples Federico II), Mario Giuliano(Regione Campania), F. Leccia(Ceinge Biotecnologie Avanzate (Italy))
Cited by 0
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282